Is ReNeuron Group Plc The Perfect Partner For BTG plc And Shire PLC In Your Portfolio?

Should you add ReNeuron Group Plc (LON: RENE) alongside BTG plc (LON: BTG) and Shire PLC (LON: SHP) to your portfolio?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in stem cell therapy company ReNeuron (LSE: RENE) have surged by over 10% today after the company announced that it has extended its research collaboration with Australian peer, Benitec. The decision to do so comes after the two companies yielded positive results from early stage studies and, looking ahead, they are optimistic regarding the future potential of their collaboration.

In fact, ReNeuron stated today that it is excited about the prospects for its exosome platform, especially as a potential new therapeutic approach that targets cancer. Furthermore, the company believes that its CTX-derived exosomes may eventually become a new pipeline of cancer therapeutic candidates, which is excellent news for ReNeuron’s long term growth outlook.

Transitional Period

Of course, ReNeuron remains a loss-making company. In fact, during the last four years its bottom line has been in the red and, looking ahead to the next two years, it is expected to see its pretax loss widen from £7.8m to almost £12m.

Should you invest £1,000 in Shopify right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Shopify made the list?

See the 6 stocks

However, looking ahead to financial year 2017, ReNeuron is forecast to post a pretax profit of £26m, as it is expected to see revenue increase from a very small amount to around £40m. As such, investor sentiment in the company could rapidly improve and push the company’s share price higher. In fact, it appears as though investors are already beginning to price in the company’s anticipated top and bottom line transition, with ReNeuron’s shares being up 65% already this year.

There could, though, be much more to come over the medium to long term. That’s because ReNeuron is expected to post earnings per share of 1.56p in financial year 2017 and, with its shares currently trading at 5.75p, it equates to a forward price to earnings (P/E) ratio of just 3.7. This is extremely low and, while there is a good chance that ReNeuron’s guidance will change over the next couple of years, there appears to be a sufficiently wide margin of safety to make the risk/reward ratio appear to be highly appealing.

Sector Peers

Of course, it could be prudent to combine ReNeuron with other, larger health care companies such as BTG (LSE: BTG) and Shire (LSE: SHP) (NASDAQ: SHPG.US). That’s because they offer greater stability and a more robust earnings profile, so a combination should be able to provide reduced company specific risk and greater consistency over the medium to long term.

And, looking ahead, both Shire and BTG appear to offer considerable potential rewards, too. Like ReNeuron, BTG is expected to rapidly improve its bottom line, with it set to rise from a pretax profit of £26m last year, to as much as £130m next year. If met, that would represent growth of 5x in just two years, which would be a stunning performance and could stimulate investor sentiment in the company moving forward.

Meanwhile, Shire trades on a price to earnings growth (PEG) ratio of just 1.1, which is relatively low for such a large company and compares very favourably to its large pharmaceutical peers. Therefore, it could be a strong performer even though its shares have already risen by 17% during the course of 2015.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the S&P 500 be heading for an almighty crash?

Christopher Ruane shares his take on why he thinks the S&P 500 could be heading for a big fall at…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Down 64%, this FTSE 250 stock offers a 13% dividend yield for investors

This struggling investment banker has suffered significant losses in the past five years, but it has the second-highest yield on…

Read more »

Investing Articles

1 stock market ETF I’ve been buying during the sell-off

The stock market's been all over the place in April, creating a fertile breeding ground for long-term buying opportunities.

Read more »

Investing Articles

As the Sainsbury share price bucks the price-war trend on FY results, I examine the dividend prospects

The J Sainsbury share price has been regaining ground, despite growing fears of intense competition in the supermarket sector.

Read more »

The words "what's your plan for retirement" written on chalkboard on pavement somewhere in London
Investing Articles

Should I invest in a Stocks and Shares ISA or a SIPP to retire early?

Early retirement is the ultimate goal for many investors, but choosing between a Stocks and Shares ISA and a pension…

Read more »

Investing Articles

Is now a great time to consider buying Greggs shares?

Greggs shares have been hammered in 2025. But have they now fallen too far? Paul Summers takes another look at…

Read more »

Investing Articles

Is it still a great time to buy cheap shares as stock market crash fears recede?

Fear of a stock market crash can trigger panic selling... but that surely can't be the best thing to do…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

The Vodafone share price is 24% undervalued, according to analysts

Our writer’s been looking at the latest targets for the Vodafone share price. Although there’s a wide variation, the average…

Read more »